Health‑advertising researcher Erin Willis at the University of Colorado-Boulder said consumers are now bombarded with GLP-1 ...

The changing market is forcing the drugmakers to hire people with more consumer-focused expertise, strike more deals with ...

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.

US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.

While the drugs have become spectacularly popular, their high prices, along with spotty insurance coverage, have left them ...

Weight-loss drugs known as GLP-1s are transforming health care. Some people who struggled for years to shed pounds experience ...

Earlier this week, the FDA approved Eli Lilly and Company’s LLY rival Novo Nordisk’s NVO oral version of the obesity drug ...

Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm ...

Fewer people in the U.S. are drinking alcohol these days. The holidays have long been a season to overindulge, whether that means too many glasses of wine or too many cookies. But this year may be ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

With the oral version of the slimming drug, the Danish company aims to regain ground, win over millions of patients and strengthen its position against competitors such as Eli Lilly.

People older than 65 represent prime targets for weight loss medications. The prevalence of obesity hovers around 40% in ...